Metabolism of COVID-19 antibodies from convalescent plasma suggests possible safe treatment for high risk children

Johns Hopkins Medicine researchers report that a prospective study of 14 infants and children demonstrated that convalescent plasma—a blood product collected from patients recovered from infections with the coronavirus (SARS-CoV-2) that causes COVID-19— was safe in high risk children infected with or exposed to the virus. The study, published Jan. 25 in the journal JCI Insight, showed that SARS-CoV-2 antibodies were metabolized similarly in children of all ages and weights.